<?xml version="1.0" encoding="UTF-8"?>
<ref id="B1">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ahmad</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Ullah</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Sadiq</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Ayaz</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Rahim</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Rashid</surname>
    <given-names>U.</given-names>
   </name>
   <etal/>
  </person-group>. (
  <year>2019</year>). 
  <article-title>Pharmacological evaluation of aldehydic-pyrrolidinedione against HCT-116, MDA-MB231, NIH/3T3, MCF-7 cancer cell lines, antioxidant and enzyme inhibition studies</article-title>. 
  <source>Drug Des. Devel. Ther.</source>
  <volume>13</volume>:
  <fpage>4185</fpage>. 
  <pub-id pub-id-type="doi">10.2147/DDDT.S226080</pub-id>
  <?supplied-pmid 31849450?>
  <pub-id pub-id-type="pmid">31849450</pub-id>
 </mixed-citation>
</ref>
